Outlook Therapeutics, Inc. (OTLK) stock
OTLKNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends September 30
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Aug 18, 2026Score 4/30
$0.40−0.01 (-1.69%)
Close on Nov 19, 2026Market cap $97.62MP/E –Yield –
Outlook Therapeutics pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Outlook Therapeutics's pe ratio was 3.1× on Jul 31, 2025.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2025 | Jul 31, 2025 | 3.1× | – |
See a number that looks wrong?